Literature DB >> 19478766

A change of strategy in the war on cancer.

Robert A Gatenby1.   

Abstract

Entities:  

Mesh：

Year:  2009        PMID： 19478766     DOI： 10.1038/459508a

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  4 in total

1.  An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines.

Authors:  Jennifer D Davidson; Liandong Ma; Michael Flagella; Sandaruwan Geeganage; Lawrence M Gelbert; Christopher A Slapak
Journal:  Cancer Res       Date:  2004-06-01       Impact factor: 12.701

2.  Suppression of lung tumor formation by the regulatory subunit of ribonucleotide reductase.

Authors:  Ashish Gautam; Gerold Bepler
Journal:  Cancer Res       Date:  2006-07-01       Impact factor: 12.701

3.  Pretherapy nuclear factor-kappaB status, chemoradiation resistance, and metastatic progression in esophageal carcinoma.

Authors:  Julie G Izzo; Arlene M Correa; Tsung-Teh Wu; Usha Malhotra; Clifford K S Chao; Rajyalakshmi Luthra; Joe Ensor; Alexander Dekovich; Zhongxing Liao; Walter N Hittelman; Bharat B Aggarwal; Jaffer A Ajani
Journal:  Mol Cancer Ther       Date:  2006-11       Impact factor: 6.261

4.  Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein.

Authors:  Barbara Scappini; Simona Gatto; Francesco Onida; Clara Ricci; Vladimir Divoky; William G Wierda; Michael Andreeff; Li Dong; Kimberly Hayes; Srdan Verstovsek; Hagop M Kantarjian; Miloslav Beran
Journal:  Cancer       Date:  2004-04-01       Impact factor: 6.860
  4 in total
  101 in total

Review 1.  Control dominating subclones for managing cancer progression and posttreatment recurrence by subclonal switchboard signal: implication for new therapies.

Authors:  Shengwen Calvin Li; Katherine L Lee; Jane Luo
Journal:  Stem Cells Dev       Date:  2011-11-02       Impact factor: 3.272

2.  Fighting against cancer by integrative medicine.

Authors:  Zhao-you Tang
Journal:  Chin J Integr Med       Date:  2012-05-02       Impact factor: 1.978

3.  An elementary approach to modeling drug resistance in cancer.

Authors:  Cristian Tomasetti; Doron Levy
Journal:  Math Biosci Eng       Date:  2010-10       Impact factor: 2.080

Review 4.  The Evolution and Ecology of Resistance in Cancer Therapy.

Authors:  Robert Gatenby; Joel Brown
Journal:  Cold Spring Harb Perspect Med       Date:  2018-03-01       Impact factor: 6.915

5.  Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer.

Authors:  Pedro M Enriquez-Navas; Yoonseok Kam; Tuhin Das; Sabrina Hassan; Ariosto Silva; Parastou Foroutan; Epifanio Ruiz; Gary Martinez; Susan Minton; Robert J Gillies; Robert A Gatenby
Journal:  Sci Transl Med       Date:  2016-02-24       Impact factor: 17.956

6.  Evolutionary dynamics in cancer therapy.

Authors:  Jessica J Cunningham; Robert A Gatenby; Joel S Brown
Journal:  Mol Pharm       Date:  2011-08-23       Impact factor: 4.939

7.  For cancer, seek and destroy or live and let live?

Authors:  Nicolas André; Eddy Pasquier
Journal:  Nature       Date:  2009-07-16       Impact factor: 49.962

8.  The evolution of drug resistance and the curious orthodoxy of aggressive chemotherapy.

Authors:  Andrew F Read; Troy Day; Silvie Huijben
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-20       Impact factor: 11.205

9.  Forty years on from Nixon's war, cancer research 'evolves'.

Authors:  Nadia Drake
Journal:  Nat Med       Date:  2011-07-07       Impact factor: 53.440

10.  Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas.

Authors:  Marco Losa; Fausto Bogazzi; Salvo Cannavo; Filippo Ceccato; Lorenzo Curtò; Laura De Marinis; Donato Iacovazzo; Giuseppe Lombardi; Giovanna Mantovani; Elena Mazza; Giuseppe Minniti; Maurizio Nizzoli; Michele Reni; Carla Scaroni
Journal:  J Neurooncol       Date:  2015-11-27       Impact factor: 4.130
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.